Related Experiment Video
Updated: Aug 23, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Evolving trends in yttrium-90 radioembolization research: a comprehensive bibliometric study
Tao Pan1, Yuhang Wang2, Hongmin Li3
1Department of Ultrasound, Seventh Medical Center of Chinese PLA General Hospital, Beijing, China.
Objective:
Yttrium-90 (Y-90) radioembolization has become a key therapeutic option for liver malignancies and is expanding into extrahepatic applications. This study aims to provide a Y-90-focused, field-wide bibliometric map that links global research trends to practice-defining contexts and explicitly contrasts glass versus resin microspheres and primary versus metastatic liver disease.
Materials And Methods:
The Web of Science Core Collection was queried for articles and reviews from 2005 to 12 July 2024. CiteSpace, VOSviewer, and Bibliometrix were employed to visualize annual output, co-authorship and institutional networks, reference co-citation backbones, and keyword clusters and bursts. Studies were narratively classified by microsphere type (glass vs resin) and disease context (hepatocellular carcinoma vs metastatic liver cancers).
Results:
The study analyzed 2,002 publications, revealing an annual growth rate of 8%. Scientific production and collaboration were concentrated in North America and Western Europe. The co-citation core was dominated by foundational hepatocellular carcinoma outcomes and international recommendations. In sub analyses, glass microsphere literature was clustered with hepatocellular carcinoma, and segmentectomy; resin microsphere literature was concentrated in colorectal liver metastases within randomized or combination regimens. Primary-disease corpora were shown to emphasize survival and transplant pathways, whereas metastatic corpora focused on local control within multimodality care.
Conclusion:
This analysis underscores the significant growth and thematic shifts in Y-90 research, while highlighting gaps such as the need for randomized trials and long-term outcome studies. Addressing these gaps will advance Y-90 radioembolization and enhance patient care through innovation and collaboration.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
